Synthorx, spun out of Scripps Research Institute, is targeting $100m in a proposed offering half a year after it raised $63m in a series C round backed by Osage University Partners.
Synthorx, a US-based immuno-oncology drug spinout of Scripps Research Institute, has filed for a $100m initial public offering on the Nasdaq Global Market.
Founded in 2014, Synthorx is developing therapeutics, dubbed synthorins, aimed at cancer and autoimmune disorders. Synthorins are proteins that incorporate amino acids encoded by additional DNA base pairs.
The approach is based on research led by Floyd Romesberg, who specialises in expanding the genetic alphabet at Scripps, in conjunction with COI Pharmaceuticals, the incubator of…
